There are currently no clearly defined parameters available for therapy management, as the updated S3 guideline on the diagnosis and treatment of Crohn’s disease published last year states. This is a dilemma that raises the question of other indicators for evaluating the course of treatment. In the PROFILE study, a treatment strategy involving the early use of a biologic proved to be superior to the standard procedure in terms of steroid-free and surgery-free remission.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Sarcoidosis, echinococcosis & Co.
Suspected symptoms and differential diagnoses
- Cancer prevention
Constant dripping – alcohol and cancer
- Steatotic liver disease
GLP-1RA in MASH – what’s new?
- Chronic pruritus: “Tour d'horizon”
Focus on new anti-inflammatory therapeutic approaches
- Multiple sclerosis
Unexpected side effects when switching from natalizumab to a biosimilar
- "Patients W.A.I.T. Indicator"
Access to new drugs is becoming increasingly difficult
- Immunotherapy
Subcutaneously or intravenously?
- Work-related asthma